SpringWorks Therapeutics reported $49.3 million in OGSIVEO® (nirogacestat) net product revenue for the third quarter of 2024, marking a 23% increase over the previous quarter.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.